Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Scil Technology acquires rights to worldwide patents for CD-RAP from Roche Diagnostics GmbH


MARTINSRIED, Germany, October 10, 2005 – Scil Technology, a biopharmaceutical company focused on the development of dental and orthopaedic tissue regeneration products, today announced that it had acquired the worldwide patents and patent applications concerning the substance and production of the growth factor MIA/CD-RAP from Roche Diagnostics GmbH. This completes Scil Technology’s underlying basic patent portfolio allowing full use of CD-RAP in the Company’s development programme for the treatment of cartilage disorders. Scil Technology in turn licensed back the use of CD-RAP to Roche Diagnostics GmbH for their research diagnostics. Financial terms of the transactions were not disclosed.

Scil Technology is using a recombinant version of CD-RAP (rhCD-RAP) as a cartilage growth factor in its cartilage regeneration programme. rhCD-RAP is highly specific for cartilage tissue. It has been shown to play a crucial role during cartilage formation in embryonic development and in the matrix stimulation of chondrocytes in adult animals. Furthermore it has been shown to stimulate cartilage synthesis in in vitro studies with chondrocytes from osteoarthritis patients. These properties make rhCD-RAP a highly promising candidate for cartilage regeneration in indications such as chondral defects and osteoarthritis.

Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“The acquisition of this patent completes our intellectual ownership of this promising cartilage growth factor, which gives us complete freedom to operate in using CD-RAP for the development of novel cartilage regenerative products .”

ST03A, Scil’s lead regenerative cartilage product, is a biodegradable implant for the treatment of osteochondral defects such as knee injuries. It consists of a combination of rhCD-RAP and a carrier matrix allowing for controlled release of the growth factor to the defect site.


About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, bone trauma, joint cartilage defects and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany. For more information please visit: http://www.scil.com


Osteochondral defects
An osteochondral defect is a defect in the gristle or hyaline cartilage at the end of the bones, where the joint surface and some of the underlying bone has been damaged. Defects of this sort are usually the result of injuries caused by sports or automobile accidents. The defect tends to be a crater with deep sides and the joint cartilage cannot fill over the gap. Insufficient management of chondral defects will lead to further destructive joint disease.

The current common treatment for chondral defect is a reduction of pain and discomfort by lavage or shaving of the affected regions. Other approaches include the stimulation of the intrinsic healing capacity by drilling procedures (Pridie drilling) and reconstructive methods comprising osteochondral transplantation using autografts (mosaicplasty procedures) and allografts. Autologous chondrocyte transplantation (ACT) is also emerging as a new technology using artificially expanded autograft material. However, despite the extremely high need for cartilage regeneration, until now no effective treatment method for regeneration in vivo has been available.
xx


Publisher Contact Information:

Scil Technology GmbH
+49 (0)89 85651824
i.staatz@scil.com

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.

Data


26,127
Tech investments
From our Online Data Service
16,882
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.